Foundational guide
Semax Protocol: Experimental Design, Not Clinical
The circulating version specifies quantity, frequency and duration. A real protocol specifies those last, after eligibility, comparator, endpoint and analysis plan.
A semax protocol, as the word is used on forums and vendor pages, is three numbers and a duration. A protocol in the sense the word carries in research is a document written before anything happens, which commits its authors to decisions they can no longer change once the results start arriving. Those two objects share a name and almost nothing else, and the comparison is the fastest way to see what a shared schedule leaves out.
Start with the comparison rather than the argument.
| Element | What a research protocol must fix in advance | What a circulating schedule supplies |
|---|---|---|
| Eligibility | Who may take part, who may not, and on what documented basis | Nothing |
| Comparator | What the exposed condition is being compared against | Nothing, or an implied comparison against how the person felt before |
| Allocation | How participants are assigned, and by what concealed procedure | Not applicable, and not acknowledged as missing |
| Blinding | Who does not know the assignment, including whoever assesses the outcome | Nothing; the person judging the result is the person expecting it |
| Primary outcome | One outcome, one instrument, one timepoint, named before the first exposure | Whatever seemed to improve |
| Material specification | Manufacturer, batch, purity testing, storage conditions | A vendor name at best |
| Adverse event handling | Definitions, reporting route, stopping rules | Nothing |
| Analysis plan | The statistical approach, written before unblinding | Nothing |
| Registration | Public posting of the above before enrolment | Not applicable |
| Quantity and frequency | Derived last, from the items above | Stated first, and often the only content |
The last row is the point. In a research document the numbers are a consequence of everything above them. In a circulating schedule the numbers are the entire document, and each row above them has been silently deleted.
Supplier publishing lot-level data
Semax, Ascension Peptides
Every lot carries certificates from two independent laboratories. The code below halves the listed price on the vial.
The published certificate for batch 30-05260628 carries a kinetic chromogenic LAL endotoxin test to USP Chapter 85, reporting under 0.20 EU/mL against a 0.5 EU/mL limit, plus a sterility screen. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price.
- Kovera Labs and MZ Biolabs certificates per lot
- Carriage free above $250
- Dispatched same day before 2pm CST
Supplied for laboratory research use and not for human consumption. Affiliate links: a commission may be earned at no cost to the reader, and it does not affect the assessment above. Prices verified August 21, 2026.
What a semax protocol would have to commit to before it ran
Prespecification is not bureaucratic decoration. It is the mechanism that makes a result interpretable. If the outcome and the analysis are chosen after the data are seen, a study can produce an apparently positive finding from noise alone, because the analyst has selected the comparison that happened to work. Registering the plan before enrolment removes that freedom. This is why the presence or absence of a registered plan changes how much weight a finding can carry, independently of how the finding turned out.
For this compound, no such document is publicly available in the Western literature, and no trial registry identifier can honestly be cited here. That absence is not evidence about the molecule. It is a fact about what a reader is able to inspect.
Why clinical use in one country does not export as a procedure
This is where the compound differs from most research chemicals, and where careless writing goes wrong in both directions.
There is a genuine Russian clinical and regulatory history. A national authority reviewed a dossier and permitted medical use, and clinical practice followed. Saying nothing exists is false. But a clinical procedure inside a healthcare system is not a portable set of instructions. It is embedded in a specific manufactured product, a diagnostic classification that determined who received it, a clinician who made that determination, monitoring arrangements, and a supply chain with regulated quality control.
Lifting the quantitative fragment out of that arrangement discards precisely the parts that made it interpretable. What arrives on a forum is the number without the population, the schedule without the indication, the exposure without the monitoring. The rest was never optional; it was the reason the number meant anything where it originated.
The second failure runs the other way. Because the underlying studies are largely published in Russian, in journals that are not comprehensively indexed in the databases most readers search, an English search returns little and gets reported as an empty literature. That conclusion describes the search. Evidence a reader cannot retrieve is not the same as evidence that does not exist, and neither is it the same as evidence a reader can rely on. Both halves have to be said in the same breath, every time.
One further asymmetry deserves stating. A clinical procedure carries an implicit stopping rule, because a clinician observing a patient decides when to continue and when to stop, using information the document never had to write down. A schedule copied onto a forum inherits the duration and loses the judgement that governed it, and the reader has no way of knowing which of the two was doing the work.
Building a design rather than borrowing one
If the goal is a research design rather than a personal regimen, the useful exercise is to write the document that does not currently exist and see what it demands.
It demands a defined population, which forces a decision about the condition under study. It demands a primary outcome and an instrument, which forces a decision about what would count as an effect and how it would be detected. It demands a comparator, which forces the recognition that improvement over time happens without any intervention, through natural fluctuation, learning effects on repeated tests, and the shifts in self report that expectation produces. It demands a material specification, which surfaces the question of whether the substance in the container matches its label. It demands stopping rules, which forces an advance decision about what harm would look like.
The animal literature does not shortcut any of this. Rat and mouse studies of this compound established that measurable effects occur in those species under those assay conditions. Those designs were built for those species, with exposure ranges chosen for them, and their outcomes were behavioural or biochemical measures in rodents. They justify a human study rather than specifying one.
What this leaves for someone who wanted a schedule
The honest position is unsatisfying and worth stating plainly. There is real clinical experience with this compound in one jurisdiction, held in a form a Western reader cannot audit. There is a rodent literature that supports investigation and does not license a human procedure. There is no publicly registered, prespecified Western design to point at, and there is no defensible way to reconstruct one from numbers circulating on the internet.
A schedule copied from a forum is not a protocol that has been shortened. It is a different kind of document that borrowed the word.
The practical consequence is that the question "what is the protocol" has no answer to give, and the substitute question is more useful: what would somebody have to publish before an answer existed. A registered plan, a defined population, a prespecified outcome, a comparator, a material specification and an analysis written in advance. Six items, none of them exotic, none of them currently available for this compound in the open literature.
Frequently asked questions
- Does a registered study exist that I could read?
- Not in the Western registries. Records that surface in a keyword search for this compound are false matches, because a registry search engine matches text anywhere in a record and returns studies with no connection to the compound. Anyone reporting a count of trials from such a search has counted the artefact rather than the studies.
- Is a detailed personal log a protocol?
- No, and the reason is structural rather than a matter of effort. A log records what happened. A protocol commits in advance to what will be measured, in whom, against what, and how the result will be analysed. A meticulous log with daily entries still has one participant, no comparison condition, no blinding, and an outcome chosen after the fact.
- If many people follow the same schedule, does that add up to evidence?
- It adds volume, not design. A thousand unblinded self assessments share every weakness of one and add a selection effect on top, because people who felt nothing tend not to post. Repetition of a flawed measurement produces a more confident flawed measurement.
- Does the Russian clinical record supply a procedure I can follow?
- It supplies a procedure that operated inside a system with a specified product, a clinical indication and supervision. Detached from those, the numeric part is not a procedure. It is a fragment of one, and the missing parts are the ones that governed who it was appropriate for.
- What could a properly designed human study settle?
- Whether an effect exists in a defined population, at what exposure, measured on a stated instrument, relative to a control condition. That is a narrower question than most readers want answered, and it is the only kind of question this design can answer honestly.
Limitations of the evidence
This page describes what a protocol document is and sets out no schedule, quantity, interval or duration. No Western regulator has converted any study into a labelled regimen, so no authorised administration guidance exists outside the Russian product's own labelling. Semax is approved and used medically in Russia and sold in Western markets as an unapproved research chemical. It holds no FDA, EMA or MHRA authorisation, no published Western registration trial exists, and no trial registry identifier can honestly be cited for it. Much of the underlying clinical literature is published in Russian in journals that are not comprehensively indexed in English language databases, so a reader outside Russia often cannot inspect the study behind a claim. Nothing here describes or recommends human use.